Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1995-11-14
|
pubmed:abstractText |
One hundred consecutive patients with acute suppurative cholangitis were randomized in a prospective, controlled clinical trial to receive either ciprofloxacin (200 mg bd iv) or triple therapy comprising ceftazidime (1 g bd iv), ampicillin (500 mg qds iv) and metronidazole (500 mg tds iv); 46 and 44 patients in the ciprofloxacin and triple therapy groups respectively were suitable for inclusion in the analysis of efficacy. In two-thirds of the patients biliary obstruction was caused by ductal calculi and in one-third by malignant or benign strictures of the biliary tract. Bacteraemia was documented in 38% of patients in the ciprofloxacin group and in 34% of patients in the triple therapy group, while bile cultures were positive in 87% and 92% of patients in the ciprofloxacin and triple therapy groups respectively. Escherichia coli, Klebsiella spp. and Enterococcus spp. were the most common biliary isolates. Eighty-five per cent of evaluable patients in the ciprofloxacin group and 77% of those in the triple therapy group responded to therapy. The mean durations of fever, septicaemic shock and hospitalization were also similar in the two treatment groups. Six (13%) patients in the ciprofloxacin group and seven (16%) in the triple therapy group required urgent endoscopy or surgery for uncontrolled infection. Recurrence of fever after an initial response was documented in one (2%) patient receiving ciprofloxacin and in three (7%) patients receiving triple therapy. The incidences of mortality were 4% in the ciprofloxacin group and 2% in the triple therapy group. The results of this study suggest that ciprofloxacin alone is adequate empirical therapy for patients with cholangitis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0305-7453
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
855-64
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7559196-Acute Disease,
pubmed-meshheading:7559196-Aged,
pubmed-meshheading:7559196-Bacteria,
pubmed-meshheading:7559196-Bile,
pubmed-meshheading:7559196-Biliary Tract,
pubmed-meshheading:7559196-Cholangitis,
pubmed-meshheading:7559196-Ciprofloxacin,
pubmed-meshheading:7559196-Double-Blind Method,
pubmed-meshheading:7559196-Drainage,
pubmed-meshheading:7559196-Female,
pubmed-meshheading:7559196-Humans,
pubmed-meshheading:7559196-Injections, Intravenous,
pubmed-meshheading:7559196-Male,
pubmed-meshheading:7559196-Microbial Sensitivity Tests,
pubmed-meshheading:7559196-Prospective Studies
|
pubmed:year |
1995
|
pubmed:articleTitle |
Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial.
|
pubmed:affiliation |
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|